States seek $26.4B from drug firms in opioid litigation
Reprints
(Reuters) — U.S. states are seeking a combined $26.4 billion from three major drug distributors and Johnson & Johnson to settle opioid litigation against the companies, the Wall Street Journal reported on Tuesday, citing people familiar with the matter.
About a dozen attorneys general are seeking a collective $21.14 billion from the distributors, which include McKesson Corp., AmerisourceBergen and Cardinal Health, and $5.28 billion from J&J, the WSJ reported.
AmerisourceBergen declined to comment on the report, while Cardinal Health, J&J and McKesson did not respond to Reuters' requests for comment.
“We believe this latest settlement proposal would be viewed as a favorable outcome and would expect the stocks to react positively to the news as a global settlement would put the uncertainty behind,” JP Morgan analyst Lisa Gill said.
The lawsuits accuse drugmakers of overstating the benefits of opioids while downplaying the risks and allege distributors failed to flag and halt a rising tide of suspicious orders.
A closely watched opioid trial pitting New York state against McKesson, Johnson & Johnson and others was postponed in March due to the coronavirus outbreak.
Shares of McKesson were up slightly in early trade, while others were down marginally.
More insurance and risk management news on the coronavirus crisis here.
Read Next
-
US pursues claims in Purdue Pharma opioid probes: Sources
(Reuters) — U.S. prosecutors are pursuing possible penalties of nearly $13 billion to resolve investigations of OxyContin maker Purdue Pharma after uncovering evidence of criminal and civil misconduct stemming from the company's alleged role in fueling the nation's opioid crisis, people familiar with the matter said.
